The Target Enabling Package (TEP*) programme's foundation is built upon the recognition that genetic data is proving to be a powerful tool for target validation. As such, TEPs provide a critical mass of reagents and knowledge on a protein target to allow rapid biochemical and chemical exploration and characterisation of proteins with genetic linkage to key disease areas. TEPs provide an answer to the missing link between genomics and chemical biology, provide a starting point for chemical probe generation and therefore catalyse new biology and disease understanding with the ultimate aim of enabling translation collaborations and target/ drug discovery.
We are committed to generating and making available 24 high-quality TEPs by June 2020.
What is in a TEP?
Each TEP, as a minimum, contains:
Additional components of TEPs may be developed on a case-by-case basis, based upon reasonable scientific need, in collaboration with TEP target nominators:
TEPs that have been approved by our external Evaluation Group are available via the links below. PDFs are available for download from these pages:
|LIMK1||LIM domain kinase 1, human kinase domain (new)||Neuropsychiatry|
|DCLRE1A||Human DNA Cross-Link Repair 1A (new)||Cancer|
|DPAGT1||Dolichyl-Phosphate Alpha-N-Acetyl glucosaminyl transferase (new)||Neuropsychiatry and neuro genetic disorders|
|AASS||Human alpha-aminoadipic semialdehyde synthase (new)||Metabolic & Neurological disorders|
|WNK3||With no lysine kinase 3 (new)||Metabolic diseases|
|HDAC6||Ubiquitin binding domain of Human HDAC6||Oncology|
|KDM3B||Histone demethylase domain of Human KDM3B||Oncology|
|KDM4D||Histone demethylase domain of Human KDM4D||Oncology|
|PHIP||Bromodomain of Human PHIP||Oncology|
|PfBDP4B||Plasmodium falciparum Bromodomain BDP4B||Infectious diseases|
|RECQL5||Human Helicase RECQL5||Oncology|
|SETDB1||Tudor domain of Human SETDB1||Oncology|
|CDK12||Cyclin-dependent kinase 12 (CDK12), Human kinase domain||Oncology|
The target list has been derived from nominations from both academia and industry with the expertise in key disease areas that are the focus of this programme: cancer, neuropsychiatry, inflammation, infectious diseases, metabolic disorders and rare diseases. Nominations are prioritised using the following criteria:
The current target list can be downloaded here.
The target list is open for further nominations at any time using the nomination form available here which should be sent to teps[at]thesgc.org (subject: TEP%20Target%20Nomination) . We will get back to you as soon as possible to discuss your nominations.
We work closely with disease experts, clinicians, geneticists and industry experts in each of the key disease areas via our Target Prioritisation Networks (TPNs). These networks ensure that we prioritise our work on the targets which are most likely to lead to downstream utility once a TEP is released. The generation of the content of each TEP often directly involves collaborations with the nominator ensuring that that the TEP contains relevant and enabling reagents, data and knowledge.
Each TEP is carefully scrutinised by the TEP Evaluation Group, chaired by Prof. Mike Ferguson (Dundee), which makes the final decision on whether a TEP is suitable to be accepted for release to the public.
Our extensive network of partners and collaborators ensures that our TEPs are rapidly taken up and their contents used to study the biochemistry, structural and chemical biology of the target concerned.
For more information regarding any aspect of TEPs and the TEP programme, please get in touch with us using the email address teps[at]thesgc.org.
|*TEP Logo designed by Claire Strain-Damerell|